IP Library › Granted Patent US 12699096
Granted Patent B2
US 12699096 · App. 18/304,741 · Granted Aug 4, 2026

Method of detecting lung cancer

Inventors: Rashid Bux (Vancouver, CA); Daniel Sitar (Winnipeg, CA)
Assignee: BIOMARK CANCER SYSTEMS INC.
G01N33/5752G01N33/6812G01N2800/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12699096
App. No.
18/304,741
Granted
Aug 4, 2026
Kind
B2
Abstract

A biomarker panel and method for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof.

Claims (12)

1 . A method for processing a human clinical urine sample, the method comprising obtaining a urine sample from a subject clinically assessed as having or suspected of having lung cancer, and quantifying a panel of metabolites in said urine sample, the panel comprising at least one urinary metabolite selected from C5:1, C10:1, ADMA, C5-OH, and SDMA.

2 . The method of claim 1 , wherein the panel comprises at least two of said urinary metabolites.

3 . The method of claim 1 , wherein the panel comprises at least three of said urinary metabolites.

4 . The method of claim 1 , wherein the at least one urinary metabolite comprises C5:1.

5 . The method of claim 1 , wherein the at least one urinary metabolite comprises C10:1.

6 . The method of claim 1 , wherein the at least one urinary metabolite comprises ADMA.

7 . The method of claim 1 , wherein the at least one urinary metabolite comprises C5-OH.

8 . The method of claim 1 , wherein the at least one urinary metabolite comprises SDMA.

9 . The method of claim 1 , wherein the panel of metabolites further comprises at least one further urinary metabolite selected from DMA and kynurenine.

10 . The method of claim 9 , wherein the at least one further urinary metabolite comprises DMA.

11 . The method of claim 9 , wherein the at least one further urinary metabolite comprises kynurenine.

12 . The method of claim 1 , wherein the panel of metabolites further comprises at least one further urinary metabolite selected from spermidine, ornithine, arginine, and methionine.